Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538665 · ClinicalTrials.gov registry record
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
A clinical trial of Ovarian Cancer and Endometrial Cancer, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT03538665 is a study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 1,500 participants, above the 724-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (107% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03538665, a study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
BACKGROUND: Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing. Also, this cancer is becoming more common and deadly for black women than white women. Researchers want to find better ways to take samples and test them for this cancer. They want to study this for a racially diverse population. One way to take samples might be from a tampon. If identified early, endometrial cancer can be highly curable; however, the earliest stages may be asymptomatic, and clinical symptoms are often missed. Combining sensitive molecular testing approaches with non-invasive sampling techniques may to lead to the development of novel endometrial cancer early detection approaches with the potential to overcome disparities in access to care and time to diagnosis and treatment. In contrast to endometrial cancer, ovarian cancer is typically detected at advanced stages with poor survival since symptoms manifest only late in the disease process and are very unspecific. Racial disparities in ovarian cancer incidence and mortality are also much less pronounced. Racial disparities can manifest particularly when screening, symptom appraisal and early detection, and effective treatment interventions have important roles in determining outcomes of cancers. OBJECTIVES: The purpose of this study is to see if it is possible and acceptable for individuals to have an endometrial or ovarian sample collected by using a tampon placed in the vagina. The investigators will look at DNA in these samples. DNA is the genetic information participants inherited from their parents. The investigators want to see whether the investigators can find changes in DNA and proteins related to endometrial or ovarian cancer from tampon samples. Tests on the samples from tampons will help to understand endometrial and ovarian cancer. The samples collected during this study will be used for research related to both endome
Conditions Studied
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2026-08-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03538665
The ClinicalTrials.gov registry entry for NCT03538665 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 724-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (107% higher). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03538665 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT03538665 about?
NCT03538665 is a clinical study titled "The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons". BACKGROUND: Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing. Also, this cancer is becoming more common and deadly for black women than white women. Researchers want to find better ways to take ...
What is the current status of trial NCT03538665?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2019-07-01. Estimated completion is 2026-08-11.
What conditions does trial NCT03538665 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Endometrial Cancer Precursors, Complex Atypical Endometrial Hyperplasia.
Who is sponsoring clinical trial NCT03538665?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03538665 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.